34 Results for "

senescent cell

" in MedChemExpress (MCE) Product Catalog:
Products (34)

34 Results for "senescent cell" in MCE Product Catalog:

Cat. No.: HY-N1458R
CAS No.: 52012-29-0
Isoschaftoside (Standard) is the analytical standard of Isoschaftoside. This product is intended for research and analytical applications. Isoschaftoside, a C-glycosylflavonoid from Desmodium uncinatum root exudate, can inhibit growth of germinated S. hermonthica radicles. Isoschaftoside reduces reactive oxygen species (ROS) and induces proliferation in senescent cells. Isoschaftoside activates autophagy. Isoschaftoside can be used for anti-tumor, anti-inflammatory, antioxidant, antihypertensive, hepatoprotective and nematicidal study.
loading...
    loading...
Cat. No.: HY-178984
CAS No.: 3095278-75-1
PI3Kα-IN-28 (Compound 23) is an efficient dual targeted PI3K/BRD4 inhibitor. PI3Kα-IN-28 can inhibit the proliferation of various cells, such as KYSE180 and KYSE450 cells. PI3Kα-IN-28 can concentration dependently inhibit migration and colony formation, induce G0/G1 phase arrest, significantly inhibit DNA synthesis, and significantly increase the proportion of senescent cells. PI3Kα-IN-28 can inhibit the expression of p-AKT and c-Myc and activate the AMPK-p27 pathway. PI3Kα-IN-28 can be used for research on cancers such as esophageal cancer .
loading...
    loading...
Cat. No.: HY-182898
CAS No.: 3051812-84-8
Target:  

Apoptosis Glycosidase

Research Areas:  

Inflammation/Immunology

Gal-dMor-Gem is a selective senescent cell scavenger, Apoptosis inducer, and a prodrug of Gemcitabine (HY-17026). Gal-dMor-Gem releases Gemcitabine upon activation by Esterases and β-gal. Gal-dMor-Gem reduces SA-β-gal, preferentially induces apoptosis in senescent cells, regulates apoptosis-related proteins, accumulates in senescent tissues, and ameliorates senescence-related organ phenotypes. Gal-dMor-Gem is applicable to research on chemotherapy-induced senescence .
loading...
    loading...
Cat. No.: HY-P72064
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: LIMS1; LIM And senescent cell Antigen-Like Domains 1; LIM Zinc Finger Domain Containing 1; Renal Carcinoma Antigen NY-REN-48; Particularly Interesting New Cys-His Protein 1; LIM-Type Zinc Finger Domains 1; PINCH1; senescent cell Antigen; PINCH; PINCH-1; L
Species:  
Mouse
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-187365
Target:  

Glycosidase

Research Areas:  

Inflammation/Immunology

UCM-17017 is a tetrasubstituted cyclohexene inhibitor that inhibits the activity of senescent cell SA-β-gal with an IC50 of 0.4 μM. UCM-17017 selectively reduces the viability of senescent cancer cells, and this effect is stronger than its impact on proliferating cells. UCM-17017 binds to human serum albumin with a KD of 230 μM. UCM-17017 reduces collagen deposition and decreases the expression of the inflammatory marker Ccl2 in a mouse model of pulmonary fibrosis. UCM-17017 can be used in studies related to senescence and pulmonary fibrosis .
loading...
    loading...
Cat. No.: HY-183307
Target:  

mTOR STAT

Research Areas:  

Neurological Disease Cancer

mTOR-IN-29 (Compound 4k) is an mTOR inhibitor with a IC50 of ~120 nM. mTOR-IN-29 inhibits mTOR kinase activity without affecting the phosphorylation of STAT3. mTOR-IN-29 acts as a cytotoxic agent against proliferating and senescent cells. mTOR-IN-29 can be used in studies related to glioblastoma .
loading...
    loading...
Cat. No.: HY-P85327
Synonyms: LIMS1; PINCH; PINCH1; LIM and senescent cell antigen-like-containing domain protein 1; Particularly interesting new Cys-His protein 1; PINCH-1; Renal carcinoma antigen NY-REN-48

Host:  

Mouse

Application:  

WB, ICC/IF, FC, ELISA

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-135146R
CAS No.: 2170136-65-7
Synonyms: (R)-GSK3482364 (Standard)
Research Areas:  

Cancer

GSK-3484862 (Standard) is the analytical standard of GSK-3484862 (HY-135146). This product is intended for research and analytical applications. GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma .
loading...
    loading...
Cat. No.: HY-135146G
CAS No.: 2170136-65-7
Synonyms: (R)-GSK3482364 (GMP)
GSK-3484862 GMP is GSK-3484862 (HY-135146) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma .
loading...
    loading...
Cat. No.: HY-152179
CAS No.: 2143464-25-7
Target:  

PROTACs Bcl-2 Family

Research Areas:  

Inflammation/Immunology Cancer

PZ15227 is a potent and selective Bcl-XL PROTAC degrader with a DC50 of 46 nM, and its Ki values for Bcl-XL, Bcl-2 and Bcl-w are 1.90 nM, 3.52 nM and >1 mM, respectively. PZ15227 recruits Bcl-XL to CRBN, induces polyubiquitination of Bcl-XL and promotes its proteasome-dependent degradation, thereby selectively killing senescent cells that rely on Bcl-XL for survival without causing severe thrombocytopenia. PZ15227 can be used for research related to age-related diseases, aging and renal cancer .
loading...
    loading...
Cat. No.: HY-134310
CAS No.: 1353586-18-1
Target:  

Heme Oxygenase (HO)

Research Areas:  

Inflammation/Immunology

QC-308 hydrochloride is a HO-1/HO-2 inhibitor, with an IC50 of 0.27 μM against rat HO-1 and an IC50 of 0.46 μM against rat HO-2. QC-308 hydrochloride inhibits the activities of rat HO-1 and HO-2 in carbon monoxide generation assays using spleen and brain microsomes, respectively. QC-308 hydrochloride also exhibits senolytic activity, reducing the survival rate of adipogenic progenitor cells in skeletal muscle fibers of senescent mice and human skeletal muscle myoblasts. QC-308 hydrochloride is applicable for senescence-related research .
loading...
    loading...
Cat. No.: HY-182604
CAS No.: 1353712-58-9
Target:  

Heme Oxygenase (HO)

Research Areas:  

Inflammation/Immunology

QC-308 is a HO-1/HO-2 inhibitor, with an IC50 of 0.27 μM against rat HO-1 and an IC50 of 0.46 μM against rat HO-2. QC-308 inhibits the activities of rat HO-1 and HO-2 in carbon monoxide generation assays using spleen and brain microsomes, respectively. QC-308 also exhibits senolytic activity, reducing the survival rate of adipogenic progenitor cells in skeletal muscle fibers of senescent mice and human skeletal muscle myoblasts. QC-308 is applicable for senescence-related research .
loading...
    loading...
Cat. No.: HY-184158
HATC is a HIF-1α AUTAC degrader. HATC links HIF-1α to LC3 to form a ternary complex that undergoes degradation via the autophagy-lysosome fusion pathway. HATC induces dose-dependent HIF-1α degradation in multiple cell types. HATC reduces visceral fat accumulation, hepatic lipid deposition, senescent cell aggregation, and bone loss; alleviates age-related intervertebral disc degeneration, liver dysfunction, kyphosis, and alveolar dilation; decreases circulating lactic acid levels; improves physical performance; and reverses age-related changes in granulocyte proportions. HATC extends median and maximum lifespan, reduces transcriptomic age, and causes no obvious persistent toxicity. HATC can be used in the research of age-related diseases (pink: LC3 ligand (HY-50759); blue: HIF-1α ligand (HY-P10426); Linker: (HY-W008264)) .
loading...
    loading...
Cat. No.: HY-L034M
381 compounds

Research has shown that drugs targeting aging pathways demonstrate promising potential in models of age-related diseases such as Alzheimer's disease, cardiovascular diseases, metabolic syndrome, osteoarthritis, and various malignancies. This suggests that intervening in the biological processes of aging may enable synergistic prevention and treatment of multiple chronic diseases. Against the backdrop of the gradual elucidation of core aging mechanisms-including cellular senescence, telomere attrition, epigenetic dysregulation, and chronic inflammation anti-aging research has shifted from traditional phenotypic interventions toward targeting key pathways that regulate biological age.

The MCE Anti-Aging Compound Library Mini is precisely built upon this cutting-edge concept. It focuses on aging-related targets validated through genetic or functional studies, comprising 381 compounds designed to provide systematic research tools for aging biology and intervention strategy development. The library covers core mechanisms such as mTOR, SIRT, energy metabolism, clearance of senescent cells, optimization of mitochondrial function, and telomere maintenance. For each target, 1-5 compounds with clear activity and strong representativeness have been carefully selected, spanning the entire translational spectrum from preclinical tool molecules to clinically investigational drugs.